The product is being co-marketed by Bayer and Fournier Pharma. It is particularly useful for patients with nocturnal asthma who are still experiencing frequent breakthrough symptoms despite optimal cortico-steroid therapy. The product is bioequivalent to Risperdal oral tablets. The solution is compatible with water, coffee, orange juice or low-fat milk, but not cola or tea. The drug was originally approved only for the treatment of non-small cell lung cancer.
Subsequent cycles consist of once-weekly infusions for three consecutive weeks out of every four.
The drug was originally approved only for the prophylaxis of thromboembolic disorders during orthopedic surgery of the hip or knee. The recommended dosage for the new indications is 40 mg once daily, by SC injection into the abdomen. The recommended dosage is one applicator full intravaginally once daily at bedtime for five days. Monograph revisions The product monographs of several Glaxo Wellcome products have been revised. Phenytoin may decrease the myeloblative effect of busulfan, due to increased busulfan clearance.